Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.

@article{Olivieri1998FactorsAH,
  title={Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.},
  author={Antonella Olivieri and Massimo Offidani and Mauro Montanari and L Ciniero and I Cantori and L Ombrosi and C M Masia and Riccardo Centurioni and Stefano Mancini and Marino Brunori and Piera Leoni},
  journal={Haematologica},
  year={1998},
  volume={83 4},
  pages={329-37}
}
BACKGROUND AND OBJECTIVE While the minimum number of CD34+ cells required for complete and long-lasting engraftment is quite well established, there is not general agreement about the optimal number of CD34+ per kg needed in order to obtain engraftment as rapidly as possible. In the present study we assess factors affecting hemopoietic recovery and the optimal peripheral blood progenitor cell (PBPC) number for rapid engraftment in patients treated with high-dose therapy. DESIGN AND METHODS We… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation • 2012
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Factors that influence collection and engraftment of autologous peripheral blood progenitor cells

W Bensinger, F Applebaum, S Rowley
J Clin Oncol • 1995
View 3 Excerpts

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1995
View 1 Excerpt

progenitor cell collections in 692 patients after the administration of myeloabla - tive chemotherapy

S Siena, M Bregni, B Brando
1995

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1994
View 2 Excerpts

Similar Papers

Loading similar papers…